Skip to content
Screener

Eli Lilly LLY Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$17.6BBeat by $1.5B
EPS$7.02Beat by $1.33
Revenue estimate$16.1B
EPS estimate$5.69

Next report

Oct 29, 2026 (In 3 weeks)
Revenue estimate$22.3B
EPS estimate$9.92

Financials

Q3 2025

Income statement

See full
Revenue$17.6B+53.9%
Gross profit$14.6B+57.4%
Net income$5.6B+475%
EPS (diluted)$6.21+480%

Balance sheet

See full
Cash & equivalents$9.8B+191%
Total debt$42.5B+36.6%
Total equity$23.8B+67.1%
Total assets$114.94B+52.0%

Cash flow

See full
Operating cash flow$8.8B+138%
CapEx$2.1B+54.5%
Free cash flow$6.7B+186%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$684B-14.3%
Enterprise value$716.71B-13.2%
P/E37.1×-58.2×
P/S11.5×-8.0×

Profitability

See full
Gross margin83%+2.1pp
Net margin31%+10.5pp
FCF margin15.6%—

Returns & leverage

See full
Return on equity96.8%+31.1pp
Debt / equity1.8×-0.4×
Current ratio1.5×+0.3×

Segments

By product

See full
Mounjaro$6.5B+109%
Zepbound$3.6B+185%
Verzenio$1.5B+7.4%
Other cardiometabolic health$1.1B+1.4%
Trulicity$1.1B-19.2%

By segment

See full
Reportable Segment$17.6B+53.9%

FAQ

When did Eli Lilly report Q3 2025 earnings?
Eli Lilly (LLY) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Eli Lilly's Q3 2025 revenue and EPS?
Eli Lilly reported revenue of $17.6B and eps of $7.02 for Q3 2025.
Did Eli Lilly beat estimates in Q3 2025?
Revenue beat the consensus estimate of $16.1B by $1.5B. EPS beat the consensus estimate of $5.69 by $1.33.
How did Eli Lilly's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 53.9% from $11.4B a year earlier and eps grew 494.9% from $1.18.
Where can I find Eli Lilly's Q3 2025 SEC filings?
You can read the 8-K earnings release (0000059478-25-000251) and the 10-Q periodic report (0000059478-25-000254) directly on SEC EDGAR. The filing index links above go to sec.gov.